Abstract
In line with major advances in therapy for metastatic melanoma in the last decade, there have also been significant improvements in imaging. 18F-fluorodeoxyglucose (FDG) PET/CT has emerged as the imaging modality of choice for identifying locoregional nodal or distant metastatic disease and also for restaging following therapy. The spatial and contrast resolution of PET has improved owing to advances in both hardware and software reconstruction. The ultimate size of disease that PET can detect depends on how metabolically active the tumour cells are within an individual lesion. On a current generation PET/CT device, disease of 8 mm or greater in size is readily detected. In some patients, however, disease as small as 2–3 mm can be detected with confidence owing to the high metabolic activity of melanoma.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Acland KM, Healy C, Calonje E, O’Doherty M, Nunan T, Page C, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol. 2001;19:2674–8.
Wagner JD, Schauwecker D, Davidson D, Coleman 3rd JJ, Saxman S, Hutchins G, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol. 1999;17:1508–15.
Even-Sapir E, Lerman H, Lievshitz G, Khafif A, Fliss DM, Schwartz A, et al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med. 2003;44:1413–20.
van der Ploeg IM, Valdes Olmos RA, Kroon BB, Wouters MW, van den Brekel MW, Vogel WV, et al. The yield of SPECT/CT for anatomical lymphatic mapping in patients with melanoma. Ann Surg Oncol. 2009;16:1537–42. doi:10.1245/s10434-009-0339-2.
Veenstra HJ, Vermeeren L, Olmos RA, Nieweg OE. The additional value of lymphatic mapping with routine SPECT/CT in unselected patients with clinically localized melanoma. Ann Surg Oncol. 2012;19:1018–23. doi:10.1245/s10434-011-2031-6.
Klode J, Poeppel T, Boy C, Mueller S, Schadendorf D, Korber A, et al. Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignancies. J Eur Acad Dermatol Venereol. 2011;25:1213–21. doi:10.1111/j.1468-3083.2010.03954.x.
Stoffels I, Boy C, Poppel T, Kuhn J, Klotgen K, Dissemond J, et al. Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. JAMA. 2012;308:1007–14. doi:10.1001/2012.jama.11030.
van der Ploeg AP, van Akkooi AC, Rutkowski P, Nowecki ZI, Michej W, Mitra A, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol. 2011;29:2206–14. doi:10.1200/JCO.2010.31.6760.
Aloia TA, Gershenwald JE, Andtbacka RH, Johnson MM, Schacherer CW, Ng CS, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol. 2006;24:2858–65. doi:10.1200/JCO.2006.05.6176.
Constantinidou A, Hofman M, O'Doherty M, Acland KM, Healy C, Harries M. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Res. 2008;18:56–60. doi:10.1097/CMR.0b013e3282f62404.
Bastiaannet E, Uyl-de Groot CA, Brouwers AH, van der Jagt EJ, Hoekstra OS, Oyen W, et al. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma. Ann Surg. 2012;255:771–6. doi:10.1097/SLA.0b013e31824a5742.
Niebling MG, Bastiaannet E, Hoekstra OS, Bonenkamp JJ, Koelemij R, Hoekstra HJ. Outcome of clinical stage III melanoma patients with FDG-PET and whole-body CT added to the diagnostic workup. Ann Surg Oncol. 2013;20:3098–105. doi:10.1245/s10434-013-2969-7.
Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol. 2014;23:11–6. doi:10.1016/j.suronc.2014.01.002.
Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998;82:1664–71.
Bastiaannet E, Oyen WJ, Meijer S, Hoekstra OS, Wobbes T, Jager PL, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg. 2006;93:243–9. doi:10.1002/bjs.5174.
Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2006;24:1178–87. doi:10.1200/JCO.2005.03.5634.
Wong C, Silverman DH, Seltzer M, Schiepers C, Ariannejad M, Gambhir SS, et al. The impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician's perspective. Mol Imaging Biol. 2002;4:185–90.
Fulham M, Kelley B, Ramshaw J, Scott A. Impact of FDG PET on the management of patients with suspected or proven metastatic melanoma prior to surgery: a prospective, multi-centre study as part of the Australian PET Data Collection Project. Society of Nuclear Medicine Annual Meeting Abstracts: Soc Nuclear Med 2007;191P.
Brady MS, Akhurst T, Spanknebal K, Gonen M, Hilton S, Coit D, Larson S. A prospective study of 18FDG-pet scanning in preoperative melanoma patients. J Clin Oncol 2004;22(14_suppl):7520.
Subesinghe M, Marples M, Scarsbrook AF, Smith JT. Clinical impact of (18)F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience. Insights into Imaging. 2013;4:701–9. doi:10.1007/s13244-013-0285-1.
Kalff V, Hicks RJ, Ware RE, Greer B, Binns DS, Hogg A. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET. Eur J Nucl Med Mol Imaging. 2002;29:506–15. doi:10.1007/s00259-001-0735-8.
Pfluger T, Melzer HI, Schneider V, La Fougere C, Coppenrath E, Berking C, et al. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. Eur J Nucl Med Mol Imaging. 2011;38:822–31. doi:10.1007/s00259-010-1702-z.
Strobel K, Bode B, Dummer R, Veit-Haibach P, Fischer DR, Imhof L, et al. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur J Nucl Med Mol Imaging. 2009;36:1774–82. doi:10.1007/s00259-009-1175-0.
Hofman MS, Constantinidou A, Acland K, Healy C, Harries M, O'Doherty M, et al. Assessing response to chemotherapy in metastatic melanoma with FDG PET: early experience. Nucl Med Commun. 2007;28:902–6. doi:10.1097/MNM.0b013e3282f1b97b.
Strobel K, Dummer R, Steinert HC, Conzett KB, Schad K, Lago MP, et al. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging. 2008;35:1786–95. doi:10.1007/s00259-008-0806-1.
McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol. 2012;30:1628–34. doi:10.1200/JCO.2011.39.1938.
Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014;4:423–33. doi:10.1158/2159-8290.CD-13-0440.
Koo PJ, Klingensmith WC, Lewis KD, Bagrosky BM, Gonzalez R. Anti-CTLA4 antibody therapy related complications on FDG PET/CT. Clin Nucl Med. 2014;39:e93–6. doi:10.1097/RLU.0b013e318292a775.
Rbah-Vidal L, Vidal A, Besse S, Cachin F, Bonnet M, Audin L, et al. Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [(1)(0)F]ICF01006, a highly promising melanoma PET tracer. Eur J Nucl Med Mol Imaging. 2012;39:1449–61. doi:10.1007/s00259-012-2168-y.
Denoyer D, Potdevin T, Roselt P, Neels OC, Kirby L, Greguric I, et al. Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. J Nucl Med. 2011;52:115–22. doi:10.2967/jnumed.110.078154.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Hofman, M.S., Hicks, R.J. (2017). Role of PET/CT in Melanoma. In: Hofman, M., Hicks, R. (eds) PET/CT in Melanoma. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-319-54741-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-54741-1_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-54740-4
Online ISBN: 978-3-319-54741-1
eBook Packages: MedicineMedicine (R0)